Brittany Kaiser Buys 9,350 Shares of Portage Biotech (NASDAQ:ALP) Stock

Portage Biotech Inc. (NASDAQ:ALP) CEO Brittany Kaiser acquired 9,350 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was bought at an average price of $5.35 per share, for a total transaction of $50,022.50. Following the purchase, the chief executive officer owned 16,766 shares in the company, valued at approximately $89,698.10. This trade represents a 126.08% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Portage Biotech Stock Performance

Shares of NASDAQ:ALP opened at $4.04 on Monday. The firm has a fifty day moving average of $10.78 and a two-hundred day moving average of $14.86. The firm has a market capitalization of $6.26 million, a P/E ratio of -0.49 and a beta of 0.54. Portage Biotech Inc. has a 12-month low of $3.20 and a 12-month high of $690.00. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01.

Portage Biotech (NASDAQ:ALP) last posted its quarterly earnings results on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The company had revenue of $0.05 million during the quarter. On average, equities analysts expect that Portage Biotech Inc. will post -14 EPS for the current fiscal year.

Analyst Ratings Changes

ALP has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. Zacks Research raised Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. HC Wainwright began coverage on shares of Portage Biotech in a research report on Monday, August 17th. They set a “neutral” rating and a $12.50 price objective on the stock. Finally, Wall Street Zen upgraded shares of Portage Biotech to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $12.50.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.